Cognitive behavior therapy using with atypical anti-psychotics to improve insight of schizophrenia

我们测试了认知行为程序与非典型抗精神病药一起使用是否改善了精神分裂症的自知力。1）试点研究帝京大学医院日间治疗中心（JCD 10）的9名诊断为精神分裂症的成员参加了认知行为程序，该程序包括22个一小时的疗程。治疗前后比较，社会技能、阴性症状、情感性症状、紊乱症状、GAS、连线测验、词语流畅性测验、自知力均有显著改善。5例非典型抗精神病药患者的应对技能、情感症状和紊乱症状的改善明显优于4例常规抗精神病药患者。2）社会技能、自知力和认知功能的相关性研究对36例精神分裂症患者进行了精神症状、自知力、认知功能和社会技能的评估。其中一个组成部分：洞察力（治疗依从性）与社交技能相关。洞察力的另一个组成部分（对精神障碍的识别）与情感症状和思维流畅性相关。3）以洞察力为重点的疗效研究概述在帝京大学医院招募了非典型抗精神病药-认知行为程序组、常规抗精神病药-认知行为程序组和非典型抗精神病药-常规门诊治疗组。每组8只。认知行为方案计划举办20次会议，将于2004年3月结束。分析该项目和非典型抗精神病药物对精神分裂症患者自知力的影响。

We tested whether cognitive-behavioral program using with atypical antipsychotics improved insight of schizophrenia.1) Pilot studyNine members of the day treatment center of Teikyo University Hospital diagnosed with schizophrenia (JCDlO) attended the cognitive behavior program which consisted of 22 one-hour sessions. As compared with pre and post treatment, social skills, negative symptoms, affective symptoms, disorganized symptoms, GAS, the trail making test, the word fluency test, insight were significantly improved. Modification of coping skills, affective symptoms, and disorganized symptoms of 5 members with atypical antipsychotics improved significantly more than 4 members with conventional antipsychotics.2) Correlational study among social skills, insight, and cognitive functioning Thirty six diagnosed with schizophrenia (ICDlO) were assessed with psychiatric symptoms, insight, cognitive functioning, and social skills. One component of :insight (treatment compliance) was associated with social skills. Another component of insight (recognition of mental disorder) was associated with affective symptoms and thought fluency.3) Outline of efficacy study focused on insightAtypial antipsychotics-cognitive behavior program group, conventional antipsychotics-cognitive behavior program group, and atypial antipsychotics-usual outpatient treatment group were recruited at Teikyo University Hospital. The number of each group was 8. The cognitive behavioral program was planned 20 sessions, and will be finished until March 2004. The effects of the program and atypical antipsychotics on insight of schizophrenia will be analyzed.